D.A. Davidson & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
D.A. Davidson & Co's XBI Position: Q1 2026 in Review
D.A. Davidson & Co reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 5% in Q1 2026, selling an estimated $52.9K and leaving 8,128 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #920.
D.A. Davidson & Co first reported a position in XBI in Q4 2016 and has held it in 38 quarters since. The position peaked at $4.02M in Q1 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- D.A. Davidson & Co held 8,128 shares of State Street SPDR S&P Biotech ETF worth $1.04M as of Q1 2026.
- D.A. Davidson & Co sold 424 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $52.9K.
- State Street SPDR S&P Biotech ETF made up 0.01% of D.A. Davidson & Co's portfolio in Q1 2026, its #920 holding.
- D.A. Davidson & Co first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 38 quarters since.
- D.A. Davidson & Co's State Street SPDR S&P Biotech ETF position peaked at $4.02M in Q1 2024.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on D.A. Davidson & Co's 13F filing for Q1 2026, filed 5 May 2026.